Biotech news for Thursday, May 14, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Earnings Call Insights: Dyadic International (DYAI) Q1 2026 Management View “Over the last several years, we have worked to transform Dyadic from a platform technology company into a commercially focused biotechnology company capable of generating recurring re…
Earnings Call Insights: Altimmune (ALT) Q1 2026 Management View "In April, we completed an oversubscribed public offering resulting in $225 million in gross proceeds" and "the proceeds from the April offering, along with our existing funds, resulted in a cash…
Earnings Call Insights: Precigen (PGEN) Q1 2026 Management View "The accelerating trajectory we are seeing in revenue growth is robust." (President, CEO & Director Helen Sabzevari) "PAPZIMEOS' net product revenue for Q1 2026, the first full quarter of avai…
Earnings Call Insights: Inovio Pharmaceuticals (INO) Q1 2026 Management View "These are very busy times at Inovio as we remain focused on achieving our top priority, advancing our lead candidate, INO-3107 through the regulatory process and toward its October 3…
Earnings Call Insights: Longeveron (LGVN) Q1 2026 Management View “After I took on the role as CEO in February, we embarked on 2 immediate critical tasks, a comprehensive review of the company's assets, development and strategic plan and attracting new investm…
Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q1 2026 Management View "Since submitting GraftAssureDx to the FDA in late March, we've had a high degree of engagement from them and expect that, that will continue as we move through the review pro…
Earnings Snapshot (Seeking Alpha) More on Inovio Pharmaceuticals Inovio Pharmaceuticals, Inc. (INO) Presents at World Federation of Hemophilia World Congress - Slideshow Inovio: 'Hold' As Upcoming PDUFA For INO-3107 Is Major Inflection Point Inovio Pharmaceuti…
Medicenna Therapeutics ( MDNA:CA ) on Wednesday said it launched a marketed public offering of securities, with the size, pricing, and terms of the offering to be determined through discussions with sole agent Bloom Burton Securities . The clinical-stage immun…
Earnings Call Insights: COMPASS Pathways (CMPS) Q1 2026 Management View CEO Kabir Nath said the quarter was “validated by the confirmation of a rolling NDA submission and review and the award of a Commissioner's National Priority Voucher or CNPV,” adding, “we…
BeOne Medicines ( ONC ) announced on Wednesday that the U.S. Food and Drug Administration granted accelerated approval for its lymphoma therapy, Beqalzi, pending the outcome of an ongoing, confirmatory study. The approval allows the Switzerland-based firm to m…
design master Replimune ( REPL ), which has been critical of the FDA over its application for a melanoma treatment, is up ~30% Wednesday, the day after FDA Commissioner Marty Makary tendered his resignation. Makary left his position Tuesday amid reported press…
matejmo As speculative trades continue to fuel the 2026 market rally, heavily shorted stocks have remained firmly in focus. Recent data highlighted by Charles Schwab’s Liz Ann Sonders showed that Goldman Sachs’ “Most Short Rolling” basket has surged 24.7% year…
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q1 2026 Management View “During the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfabrio's every 4 weeks dosing regimen,” and “we ended the first…
Ironwood Pharmaceuticals ( IRWD ) lost ~12% on Wednesday after the bowel disease drugmaker announced the appointment of an interim chief financial officer following the resignation of its current CFO, Gregory Martini. On Friday, Martini, who also served as a s…
Earnings Call Insights: PDS Biotechnology Corporation (PDSB) Q1 2026 Management view Dr. Frank Bedu-Addo (President, CEO & Director) said the quarter’s “major focus was on advancing our clinical programs,” and handed the program update to the CMO, pointing…
Whitehawk Therapeutics ( WHWK ) announced on Wednesday that it has entered into a securities purchase agreement for an $87.5M private investment in public equity, or PIPE, financing, before deducting placement agent fees and other private placement expenses. T…
Palvella Therapeutics ( PVLA ) said Nasdaq approved the transfer of its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market, effective May 13. The company’s shares will continue trading under the ticker “PVLA.” CEO Wes Kaupinen said
mihailomilovanovic/E+ via Getty Images Varda Space Industries on Wednesday announced a collaboration with United Therapeutics Corporation ( UTHR ) to explore the use of microgravity to develop improved formulations of treatments for rare pulmonary disease. Var…
Earnings Call Insights: Curis, Inc. (CRIS) Q1 2026 Management View "We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma" and said the TakeAim Lymphoma study is "a single-arm registrational study with an ORR endpoint" evalu…
Mirum Pharmaceuticals ( MIRM ) priced a private offering of $600M aggregate principal amount of 0.00% convertible senior notes due 2032. The initial purchasers have a 13-day option to buy up to an additional $90M notes. Mirum plans to use about $475M